Indee Labs has made a significant advancement in engineered cell therapy manufacturing with the introduction of its Hydropore™ platform. This cutting-edge non-viral delivery system is backed by a robust portfolio of over 20 U.S. and international patents, now exclusively represented by Becker Transactions for potential acquisition or licensing.
The Hydropore™ platform effectively addresses major challenges associated with traditional viral and electroporation delivery methods. It facilitates rapid, high-yield intracellular delivery while ensuring minimal disruption to cell integrity. Collaborating with three of the top ten pharmaceutical companies and esteemed institutions such as Stanford University, UC San Francisco, and the Medical University of South Carolina, Indee Labs has engineered a system capable of delivering materials across various cell types in less than 30 seconds—without the need for viral vectors or proprietary reagents. Over 20 units have been deployed globally, with more than 1,600 chips sold.
Transformation in Cell Therapy
Ryan Pawell, Founder and CEO of Indee Labs, commented on the transformative potential of engineered cell therapies. He acknowledged the limitations of current delivery mechanisms, stating, “Hydropore™ represents a fundamentally new approach. It provides a gentle, cell-size-independent solution that improves yield, preserves cell health, and accelerates the translation from discovery to manufacturing.”
Three Pillars of Innovation
The patent portfolio surrounding Hydropore™ encompasses three core innovation pillars:
- Hydrodynamic Delivery: This technology utilizes vortex shedding-based microfluidics to gently and efficiently permeabilize the cell membrane, allowing for effective intracellular delivery.
- Electrohydrodynamic Enhancement: By employing brief post-permeabilization electrophoresis, the system facilitates direct DNA delivery to the nucleus, enhancing gene-editing efficiency.
-
Optimized Chip Design: The platform’s simple, micron-scale geometries enable high-throughput manufacturing and reproducibility using standard industry equipment.
Together, these innovations create a strong intellectual property foundation for Indee Labs, ensuring exclusivity through 2038 and beyond. Early deployments have shown performance superior to existing market leaders such as Lonza’s Nucleofector and Thermo Fisher’s Neon systems.
Market Dynamics and Opportunities
The engineered cell therapy market is experiencing rapid growth, with a compound annual growth rate (CAGR) exceeding 70% on a per-patient basis. Intracellular delivery methods represent a critical bottleneck in this market. Dean Becker, Chairman of Becker Transactions, highlighted the strategic significance of the Hydropore™ portfolio: “This portfolio gives acquirers immediate IP defensibility and a direct pathway to productization in both research and therapeutic manufacturing markets.”
Commercial Recognition and Future Prospects
Indee Labs’ technology has garnered multiple Good Design Awards, attracting interest from global pharmaceutical companies and instrument distributors. The company’s intellectual property is fully assignable, unencumbered, and comes with a comprehensive clearance letter for its foundational patent family. Hydropore™ chips and instruments have been developed in partnership with independent vendors, ensuring scalability in manufacturing.
Conclusion
Indee Labs’ Hydropore™ platform represents a transformative step forward in engineered cell therapy. By overcoming traditional delivery challenges, this innovative technology opens new avenues for research and therapeutic applications. The strategic collaboration with Becker Transactions further positions Indee Labs at the forefront of a rapidly evolving market.
Key Takeaways:
- Indee Labs introduces Hydropore™, a non-viral delivery system with a significant patent portfolio.
-
The platform addresses limitations of existing delivery methods, enhancing efficiency and cell health.
-
Three innovation pillars underpin the technology, ensuring strong intellectual property protection.
-
The engineered cell therapy market is rapidly expanding, with Hydropore™ positioned to capitalize on this growth.
-
Indee Labs has received recognition for its technology and is poised for further commercial success.
Read more → www.dispatch.com